Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world…

RT @DrImranSheikh: Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib…

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study: Objectives, The antitumor… #oncology https://t.co/jN

New research: Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study: Objectives The antitumor… https://t.co